CTMC is a joint venture between Resilience and MD Anderson Cancer Center, established to accelerate patient access to cell therapies by bridging development and manufacturing with MD Anderson’s clinical trial capabilities.

Authors

• Person: Not available Organization: Drug Target Review
  New cell therapy model accelerates cancer treatment development

Sources

• New cell therapy model accelerates cancer treatment development www.drugtargetreview.com Drug Target Review via serper

Referenced by nodes (2)

• UT MD Anderson Cancer Center entity
• CTMC entity